Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hermenegildo, C.
Right arrow Articles by Cano, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermenegildo, C.
Right arrow Articles by Cano, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction Update, Vol.6, No.3 pp.237-243, 2000
© European Society of Human Reproduction and Embryology 2000; all rights reserved

Pure anti-oestrogens

Carlos Hermenegildo1 and Antonio Cano

Dept. of Pediatrics, Obstetrics and Gynecology, University of Valencia, Spain

Received on August 19, 1999; accepted on February 21, 2000

Abstract

Pure anti-oestrogens are a group of at least five new compounds which are able to antagonize the effects of oestrogen in all tissues and species studied. The mechanism by which the pure anti-oestrogens produce their effects remains in question, but all of them are competitive antagonists of the oestrogen receptors and, moreover, have been proposed to block the shuttling of oestrogen receptors into the cell nucleus. When studied in vitro, these compounds are able to block the oestrogen-stimulated growth of breast cancer cells. In animals, their ability to block the effects of oestrogen on breast, uterus, bone, cardiovascular system and other reproductive-associated tissues has been demonstrated. ICI 182780 has been used in preliminary clinical trials in women with advanced, tamoxifen-resistant breast cancer with promising results. Clinical trials with EM-800 are under way to assess the safety and tolerance and to obtain information on its efficacy in patients who have already been treated with tamoxifen. It seems reasonable to assume that pure anti-oestrogens will be a good alternative to tamoxifen in the treatment of breast cancer and also in some non-malignant gynaecological diseases.

Key words: anti-oestrogens/ / clinical trials/ / mechanism of action/ / oestrogen receptor antagonist/ / selective oestrogen receptor modulator


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
E.V. Younglai, Y.J. Wu, T.K. Kwan, and C.-Y. Kwan
Non-genomic action of estradiol and progesterone on cytosolic calcium concentrations in primary cultures of human granulosa-lutein cells
Hum. Reprod., September 1, 2005; 20(9): 2383 - 2390.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Hermenegildo, M. C. Garcia-Martinez, J. J. Tarin, and A. Cano
Estradiol reduces F2alpha -isoprostane production in cultured human endothelial cells
Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2644 - H2649.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. E. Gargett, M. Zaitseva, K. Bucak, S. Chu, P. J. Fuller, and P. A. W. Rogers
17{beta}-Estradiol Up-Regulates Vascular Endothelial Growth Factor Receptor-2 Expression in Human Myometrial Microvascular Endothelial Cells: Role of Estrogen Receptor-{alpha} and -{beta}
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4341 - 4349.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.